trolled study conducted in 66 centers in North America and Europe. It is designed to confirm the results of the earlier Phase 3 trial by examining the safety and efficacy of a daily administration of 2 mg of TH9507 for a period of 26 weeks. The primary endpoint is a reduction of visceral adipose tissue, or VAT. In August 2006, the protocol for this second Phase 3 trial was approved by the Food and Drug Administration (FDA) in the United States through the Special Protocol Assessment (SPA) process.

"We have now secured the necessary regulatory approvals for the European arm of our trial," said Yves Rosconi, President and Chief Executive Officer of Theratechnologies. "All of the data we have presented thus far indicate that TH9507 may offer an attractive combination of efficacy and safety with potential advantages over other approaches being developed. This is potentially very good news for patients and this marks the first time that our drug is being made available to European HIV-associated lipodystrophy patients," Mr. Rosconi stated.

HIV-associated Lipodystrophy

HIV-associated lipodystrophy is characterized by a change in the distribution of adipose tissue (fat containing tissue), dyslipidemia and glucose intolerance. The changes in fat distribution include visceral fat accumulation and/or loss of subcutaneous fat, generally in the limbs and in the face. There is no treatment available for the accumulation of visceral fat found in patients with HIV-associated lipodystrophy. It is estimated that approximately 250,000 HIV-infected patients in North America and Europe suffer an excessive accumulation of visceral fat.

About ENDO

ENDO is the annual meeting of the Endocrine Society, and is the largest meeting of its type in the world. Approximately 7,000 researchers, scientists, and clinicians from across the globe have assembled in Toronto for this premier meeting of hormone research and endocrinology.
'"/>




Page: 1 2 3
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery